Detection Technology PLC (FRA:6DT)

Full Year 2025 Detection Technology Oyj Earnings Call Transcript

Feb 5, 2026 / 11:00 AM GMT

Release Date Price: €5.3

Transcript

Key Points

Positve

Detection Technology PLC (OHEL:DETEC) reported strong growth in the medical segment, with a 19% increase driven by CT and healthcare reforms in China.
The company experienced significant growth in TFT panels, with a 50% increase for the quarter and 60% for the full year, particularly driven by battery inspection.
Detection Technology PLC (OHEL:DETEC) launched its DT 2030 strategy, aiming for a 10% market growth by providing high-value X-ray detectors.
The company was recognized as the supplier of the year by GE Healthcare, highlighting its strong reputation and performance.
Detection Technology PLC (OHEL:DETEC) expects double-digit growth in the first quarter and first half of the year across all applications and regions.

Negative

Fourth quarter net sales declined by 6%, primarily due to unfavorable currency exchange rates.
Security sales decreased by almost 30%, affected by one-time events and high inventory levels with some customers.
The company's EBITA margin decreased to 12.4% from the previous year's 16.3%, impacted by lower sales and a focus on less profitable medical sales.
Cash flow was significantly down as the company increased inventories to prepare for growth amid global material shortages.
The industrial segment faced challenges, with line scan sales declining and intense competition in the Chinese market.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

DETEC.HE - Detection Technology Oyj
Full Year 2025 Detection Technology Oyj Earnings Call
Feb 05, 2026 / 11:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Detection technology and welcome to follow DET's 4th quarter results announcement. I'm pleased to be presenting to you.

Fourth quarter net sales reached â¬29.7 million a negative 6%. EBITA was 3.7 and EBITA percentage 12.4%. So some Some a couple of millions below what we 1.5 million what we achieved last year. The biggest reason for the sales decline was the currency exchange rate, which represents about 55%. So without that, the sales would be very much flattish.

But we'll be explaining a bit more, a bit closer what took place.

So if you look at the application's point of view, The sales in medical developed quite well, but then in in in security declined. Industrial sales was 7% negative

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.